biotech investing Archives

Serina Therapeutics Clears a Key Parkinson’s Hurdle -( $PFE $SER $XBI )

by John F. Heerdink, Jr. September 9, 2026 203Views 0Likes

Serina Therapeutics, Inc. (NYSE American: SER) has moved its lead Parkinson’s disease program from promise on paper to progress in patients. After an independent safety committee completed its blinded review of the first cohort in the Company’s Phase 1b registrational study, Serina received…

Digital Nasdaq billboard in Times Square highlighting Eupraxia Pharmaceuticals (NASDAQ: EPRX), its Nasdaq Global Select Market upgrade, and the upcoming eosinophilic esophagitis clinical-data catalyst.

Eupraxia Pharmaceuticals’ Nasdaq Upgrade Sets the Table for a High-Stakes EoE Catalyst -( $EPRX $SNY $XBI )

by John F. Heerdink, Jr. September 8, 2026 192Views 0Likes

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX) has moved up to the Nasdaq Global Select Market just as its lead clinical program approaches a pivotal Phase 2b interim data event. For many, the timing is rather tidy: the company is pairing greater market…

Investor-themed graphic showing Tribe Public and ACOG logos above a rising green-and-gold stock chart, dollar signs, and the Zunveyl (benzgalantamine) 5 mg, 10 mg, and 15 mg branding against a modern city backdrop.

Alpha Cognition’s Commercial Alzheimer’s Story Is Getting Harder to Ignore -( $ACOG )

by John F. Heerdink, Jr. September 6, 2026 184Views 0Likes

Alpha Cognition Inc. (NASDAQ: ACOG) has moved meaningfully beyond the familiar small-cap biotech ritual of promising future potential. Since CEO Michael McFadden’s January 15, 2026 Tribe Public luncheon presentation during the J.P. Morgan Healthcare Conference week in San Francisco, the company has paired…

Comic-book-style illustration of a confident superhero in a teal suit with an “R” molecular symbol flying above a modern city skyline. Large headline text reads “Revolution Medicines’ Moment Arrives: Why RVMD Has Wall Street’s Attention,” while surrounding signs reference Revolution Medicines, RVMD stock, innovation, cancer breakthrough and oncology leadership.

Revolution Medicines’ Moment Arrives: Why RVMD Has Wall Street’s Attention -( $IBB $RVMD $XBI )

by John F. Heerdink, Jr. September 1, 2026 220Views 0Likes

Revolution Medicines, Inc. (NASDAQ: RVMD) seems to have crossed the line that separates a compelling biotech hypothesis from a commercial oncology story: the U.S. Food and Drug Administration approved its first medicine, RASONQUE (daraxonrasib), for certain adults with metastatic pancreatic adenocarcinoma. The approval…

Tenon Medical’s Breakout Day Puts the SI-Joint Story on Wall Street’s Radar – ( $TNON )

by John F. Heerdink, Jr. August 19, 2026 157Views 0Likes

Tenon Medical, Inc. (NASDAQ: TNON) is had the sort of trading day that causes even seasoned small-cap investors to refresh their screens twice. Shares closed up $5.96, or 109.36%, to $11.41, after hitting an intraday high of $16.28..Volume exceeded 48.4 million shares—roughly…

Amwell’s Quietly Compounding Digital-Care Story Is Getting Harder to Ignore -( $AMWL )

by John F. Heerdink, Jr. August 19, 2026 235Views 0Likes

Amwell, Inc. (NYSE: AMWL, $12.40, up +152.55% YTD) is building a more investable telehealth narrative: less pandemic-era novelty, more enterprise healthcare infrastructure. Its second-quarter results suggest the company is translating a broad digital-care footprint into a steadier mix of recurring subscription revenue,…

Moderna’s Melanoma Momentum Rekindles the mRNA Growth Story—and Keeps Biotech Investors Hunting for Precision -( $EPRX $XBI $MRK $MRNA )

by John F. Heerdink, Jr. August 19, 2026 331Views 0Likes

The biotechnology market has a habit of demanding patience right up until it abruptly decides to reward it. Moderna, Inc. (NASDAQ: MRNA) recently reminded investors of that rule as enthusiasm around its personalized melanoma-vaccine program with Merck & Co., Inc. (NYSE: MRK)…

Eupraxia Pharmaceuticals: A Precision Bet on Making Food Enjoyable Again – Meet CEO At The Tribe Event – Friday, August. 21-( $EPRX $REGN $SNY $TAK )

by John F. Heerdink, Jr. August 17, 2026 251Views 0Likes

For patients with eosinophilic esophagitis, eating can become an exercise in calculated risk rather than a simple pleasure. For Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX), that burden represents both an urgent medical problem and a potentially compelling opportunity to prove that…

Fortell’s AI Hearing Aid Could Turn a Staid Medical-Device Category Into a Premium Technology Market -( $BLFY $GNNDY $GOOGL $NVDA $SONVY )

by John F. Heerdink, Jr. August 14, 2026 380Views 0Likes

The next compelling AI investment story may not sit in a data center. It may sit discreetly behind the ear. Fortell, a privately held AI-hearing-aid company, is positioning itself at the intersection of custom silicon, machine learning, clinical care, and an enormous…

Diabetes Tech’s Next Growth Cycle: Turning Innovation Into Commercial Momentum at ADCES 2026 -( $ABT $DXCM $MODD $PODD $TNDM )

by John F. Heerdink, Jr. August 7, 2026 313Views 0Likes

The diabetes-device sector is showing signs of a more interesting ailment for Wall Street: a shortage of skepticism. Tandem Diabetes Care, Inc. (NASDAQ: TNDM) is pairing renewed financial discipline with product expansion, while Modular Medical, Inc. (NASDAQ: MODD) is taking its Pivot…

Tag: biotech investing

Serina Therapeutics Clears a Key Parkinson’s Hurdle -( $PFE $SER $XBI )

Eupraxia Pharmaceuticals’ Nasdaq Upgrade Sets the Table for a High-Stakes EoE Catalyst -( $EPRX $SNY $XBI )

Alpha Cognition’s Commercial Alzheimer’s Story Is Getting Harder to Ignore -( $ACOG )

Revolution Medicines’ Moment Arrives: Why RVMD Has Wall Street’s Attention -( $IBB $RVMD $XBI )

Tenon Medical’s Breakout Day Puts the SI-Joint Story on Wall Street’s Radar – ( $TNON )

Amwell’s Quietly Compounding Digital-Care Story Is Getting Harder to Ignore -( $AMWL )

Moderna’s Melanoma Momentum Rekindles the mRNA Growth Story—and Keeps Biotech Investors Hunting for Precision -( $EPRX $XBI $MRK $MRNA )

Eupraxia Pharmaceuticals: A Precision Bet on Making Food Enjoyable Again – Meet CEO At The Tribe Event – Friday, August. 21-( $EPRX $REGN $SNY $TAK )

Fortell’s AI Hearing Aid Could Turn a Staid Medical-Device Category Into a Premium Technology Market -( $BLFY $GNNDY $GOOGL $NVDA $SONVY )

Diabetes Tech’s Next Growth Cycle: Turning Innovation Into Commercial Momentum at ADCES 2026 -( $ABT $DXCM $MODD $PODD $TNDM )

Your Guide To Staying Informed In The Markets